External validation of a nomogram for de novo bone metastasis in breast cancer: a single-center Mexican cohort
Clinical and Translational Oncology · 04.07.2026
DOI: 10.1007/s12094-026-04490-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 04.07.2026. Verfasst von Adrián Canizalez-Román und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, The Women's Hospital, Culiacán, Mexico. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Accurate identification of breast cancer patients at risk of de novo bone metastasis (BM) may support staging and treatment planning. The current study externally validated a previously published nomogram in a Mexican cohort of women with newly diagnosed breast cancer. METHODS: A retrospective external validation study was conducted in women diagnosed at a tertiary referral cancer center in Mexico during 2023. Model performance was evaluated through discrimination, calibration, and clinical utility. Discrimination was assessed using the area under the receiver operating characteristic curve (AUC-ROC) and precision-recall curve (AUC-PR). Calibration was evaluated using calibration intercept and slope, calibration plots, and logistic recalibration. Decision curve analysis assessed clinical utility. A sensitivity analysis excluding surgery status was also performed. RESULTS: The validation cohort included 293 patients, of whom 11 (3.8%) presented with de novo bone metastasis. The original model demonstrated moderate discrimination (AUC-ROC 0.81, 95% CI 0.67-0.96; AUC-PR 0.32, 95% CI 0.05-0.66). In the sensitivity analysis, AUC-ROC remained similar (0.80; 95% CI 0.66-0.95), whereas AUC-PR decreased to 0.23 (95% CI 0.03-0.52). Calibration was suboptimal, with a calibration intercept of -2.99 and a slope of 0.90, indicating systematic overestimation of risk. Recalibration improved agreement between predicted and observed risks. Clinical utility was comparable across models, with modest improvements after recalibration. CONCLUSIONS: The nomogram maintained reasonable discrimination but exhibited substantial calibration drift in this independent Mexican cohort. External validation and recalibration may be necessary before implementation in populations distinct from those used for model development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Department, The Women's Hospital, Culiacán, Mexico.
- Faculty of Medicine, Autonomous University of Sinaloa, Culiacán, Mexico.
- Gynecology Department, Women's Hospital of Sinaloa, Culiacán, Mexico.
- Family Medicine Unit No. 46, Mexican Social Security Institute, Culiacán, Mexico.
- Faculty of Medicine, Autonomous University of Sinaloa, Culiacán, Mexico. diego_arriza@outlook.com.
Zitieren
APA
Canizalez-Román, A., Llanes-Cardenas, R., Martínez-Villa, F. A., & Arriaga-Izabal, D. (2026). External validation of a nomogram for de novo bone metastasis in breast cancer: a single-center Mexican cohort. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04490-7
Vancouver
Canizalez-Román A, Llanes-Cardenas R, Martínez-Villa FA, Arriaga-Izabal D. External validation of a nomogram for de novo bone metastasis in breast cancer: a single-center Mexican cohort. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04490-7
BibTeX
@article{CanizalezRomn2026,
author = {Canizalez-Román, Adrián and Llanes-Cardenas, Romina and Martínez-Villa, Francisco Antonio and Arriaga-Izabal, Diego},
title = {External validation of a nomogram for de novo bone metastasis in breast cancer: a single-center Mexican cohort},
journal = {Clinical and Translational Oncology},
year = {2026},
doi = {10.1007/s12094-026-04490-7}
}
EUVIMED